Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bear Stearns Healthcare Conference, In Brief

Executive Summary

Abbott D2E7 advisory committee?: Abbott has "not heard anything at all" about a possible early December FDA advisory committee meeting for its anti-TNF monoclonal antibody D2E7 (adalimumab), CFO Thomas Freyman told Bear Stearns healthcare conference in New York City. Abbott does not believe "having a panel or not having a panel is going to impact our timing at all in terms of product launch." In a separate Bear Stearns presentation, Enbrel marketer Amgen Investor Relations Director Anna McDermott-Vitak said she "would be surprised" if D2E7 was not the subject of an advisory committee meeting. Abbott submitted a BLA for D2E7 in rheumatoid arthritis April 2; the company expects to launch adalimumab in the first half of 2003...

You may also be interested in...



Tricor noninfringement ruling upheld

U.S. federal appeals court upholds Chicago district court judge's noninfringement ruling on Teva's generic version of Abbott's Tricor (fenofibrate) capsules. Teva began marketing a generic of the cholesterol agent after the lower court's March 2002 ruling. In response, Abbott launched a campaign to switch Tricor capsule users to tablets (1"The Pink Sheet" Sept. 30, 2002, p. 27)...

Tricor noninfringement ruling upheld

U.S. federal appeals court upholds Chicago district court judge's noninfringement ruling on Teva's generic version of Abbott's Tricor (fenofibrate) capsules. Teva began marketing a generic of the cholesterol agent after the lower court's March 2002 ruling. In response, Abbott launched a campaign to switch Tricor capsule users to tablets (1"The Pink Sheet" Sept. 30, 2002, p. 27)...

Teva’s Generic Remeron Exclusivity Cut To Five Months By FDA Rules

Teva's generic Remeron (mirtazapine) will have only five months of marketing exclusivity from its approval date due to FDA's current interpretation of the trigger for first-to-file 180-day marketing exclusivity under the Waxman/Hatch Act, Teva reported in its Feb. 18 earnings teleconference

Related Content

UsernamePublicRestriction

Register

ID1132956

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel